COVID-19 Pathogen Analysis: Case, Transmission & Treatment
This paper provides a structured analysis of COVID-19 (coronavirus disease 2019), examining the disease from multiple clinical and epidemiological angles. Beginning with a documented first European case, the paper describes the chief complaints, disease progression, and complications associated with SARS-CoV-2 infection. It then characterizes the pathogen itself — a positive-strand RNA virus — including its morphology and environmental sensitivity. The epidemiology section covers transmission routes, disease vectors, global prevalence, at-risk populations, and notable outbreak milestones. Finally, the paper reviews diagnostic methods such as rRT-PCR and serological testing, and surveys treatment and control strategies, including quarantine protocols and antiviral medications used during the early pandemic period.
- Introduction to Coronaviruses and COVID-19: Overview of coronavirus family and COVID-19 emergence
- Typical Case Presentation and Disease Progression: First European patient symptoms, timeline, and complications
- Pathogen Characteristics of SARS-CoV-2: Morphology, classification, and environmental sensitivity of virus
- Epidemiology and Transmission: How COVID-19 spreads and its global prevalence
- At-Risk Populations and Recent Outbreaks: Vulnerable groups and key pandemic outbreak milestones
- Diagnosis, Control, and Treatment: PCR testing, serology, quarantine, and antiviral strategies
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses a specific documented case — the first European COVID-19 patient — to ground abstract clinical concepts in a concrete, traceable example with a clear timeline.
- Moves logically from the individual to the global, scaling from a single patient's symptoms to worldwide epidemiological data and outbreak milestones.
- Balances clinical detail (e.g., PO2 readings, specific antivirals) with accessible explanation, making the paper useful for both specialized and general academic audiences.
Key academic technique demonstrated
The paper demonstrates structured sectional organization, a common technique in health science writing where clinical, microbiological, epidemiological, and treatment dimensions are addressed in discrete, labeled sections. This format mirrors professional public health reporting and allows readers to locate specific types of information quickly. Each section cites relevant sources to support its claims, maintaining academic credibility throughout.
Structure breakdown
The paper is organized into four main areas: (1) a typical case study with symptom description and disease progression; (2) pathogen classification and morphology; (3) epidemiology covering transmission, vectors, prevalence, and at-risk groups; and (4) diagnosis and treatment options. This mirrors the structure of a standard infectious disease analysis report used in public health and microbiology coursework.
Introduction to Coronaviruses and COVID-19
Coronaviruses represent a family of single-stranded, enveloped, positive-strand, Nidovirales RNA viruses. The family encompasses human pathogens and pathogens of several animal species, including the previously isolated SARS-CoV (severe acute respiratory syndrome coronavirus) (Weiss & Navas-Martin, 2005). COVID-19, or coronavirus disease 2019, surfaced for the first time towards the end of 2019 and has since affected over two hundred nations. In a matter of only five months, more than 4,890,000 individuals worldwide were diagnosed with the illness. Over 100,000 individuals tested positive for the disease within a single day (Yang, Li, Sun, Zhao, & Tang, 2019).
Typical Case Presentation and Disease Progression
The first patient to contract the disease was a Chinese man aged 31 years, from Wuhan, who was hospitalized while on holiday in Paris, France, with his wife. He tested positive for COVID-19 on January 24, 2020 — the sixth day of his illness and five days after first arriving in Paris. Before beginning his vacation, he had visited a Wuhan hospital on January 16 for gout treatment (Xavier et al., 2020).
From the outset, the patient exhibited influenza-like signs and was hospitalized upon being diagnosed with thrombopenia, mild lymphopenia, and an absence of any abnormalities on his chest X-ray (Xavier et al., 2020). However, ten days after contracting the disease, his worsening oxygen saturation (PO2 = 58 mm Hg; flow nasal cannula 4 L/min), coupled with bilateral lung abnormalities — including ground-glass opacities, alveolar opacities, and reticulo-nodular syndrome discovered from chest CT scans — caused him to be transferred to intensive care. The following day, a loading dose of remdesivir was administered, followed by maintenance treatment. On January 31, he was discharged from intensive care.
Two weeks after contracting the disease, remdesivir was discontinued due to a maculopapular rash and elevation in alanine aminotransferase levels (three times the normal threshold), without eosinophilia, anaphylaxis, or systemic indications. Screening for cytomegalovirus, hepatitis B, hepatitis C, herpes simplex, and Epstein-Barr viruses revealed no active infections. Within 72 hours, his liver and skin abnormalities diminished, and another 24 hours later he was declared asymptomatic. He was discharged on February 12 (Xavier et al., 2020).
Acute COVID-19's chief complication is ARDS (acute respiratory distress syndrome), manifesting as acute respiratory failure and dyspnea, which may require mechanical ventilation. Beyond respiratory sequelae, acute COVID-19 is associated with arrhythmias, heart failure, cardiomyopathy, myocardial injury, other cardiovascular complications, encephalopathy, acute ischemic stroke, other neurological complications, and severe kidney injury, which typically requires renal replacement therapy (ECDPC, 2020).
Pathogen Characteristics of SARS-CoV-2
The microorganism responsible for COVID-19 is a virus designated SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The novel pandemic was termed COVID-19, or Coronavirus Disease 2019, by the WHO (World Health Organization) (Ouassou et al., 2020). An observational analysis of a sample of 1,420 individuals diagnosed with mild to moderate COVID-19 identified the following most widely reported signs of illness: headache (70.3% of patients), impaired sense of smell (70.2%), nasal obstruction (67.8%), asthenia (63.3%), cough (63.2%), myalgia (62.5%), rhinorrhoea (60.1%), gustatory dysfunction (54.2%), sore throat (52.9%), and fever (45.4%) (ECDPC, 2020).
From electron microscopy, SARS-CoV-2's coronavirus-specific morphology is characterized by virus particles ranging in size from 70 to 90 nm, observed in various intracellular organelles, especially vesicles (Kumar, Nyodu, Maurya, & Saxena, 2020). Preliminary insights from studies of similar viruses and laboratory research suggest the disease may decline at elevated temperatures, under ultraviolet light, and at increased humidity. Recent fine-scaled data on weather conditions and infection reports across the globe have facilitated the development of a model explaining 36 percent of the discrepancy in growth rates of the disease, based on country-specific factors (19 percent) and demography and weather (17 percent) (Kumar, Nyodu, Maurya, & Saxena, 2020).
Create your account
Always verify citation format against your institution’s current style guide requirements.